Urinary Retention Rates in Clinical Practice After Treatment With OnabotulinumtoxinA for Idiopathic Overactive Bladder

Allergan315 enrolled

Overview

This study is a retrospective chart review of patients treated with BOTOX® for idiopathic Overactive Bladder (OAB) as standard of care in clinical practice. The study will determine the rate of post procedural urinary retention requiring catheterization and identify factors that may predict urinary retention.

Study Type

OBSERVATIONAL

Enrollment

315

Conditions

Urinary Bladder, Overactive

Interventions

onabotulinumtoxinADRUG

OnabotulinumtoxinA (BOTOX®) as prescribed in clinical practice.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: -Patients treated with BOTOX® for Overactive Bladder. Exclusion Criteria: * Received botulinum toxin formulations other than BOTOX® in the bladder. * Had symptoms of OAB associated with a neurological condition. * Had a history of chronic urinary retention treated with Clean Intermittent Catheterization (CIC) or indwelling catheter.

Locations (7)

University of California, Davis

Davis, California, United States

Capital Region Urology

Irvine, California, United States

The Charlotte-Mecklenburg Hospital Authority DBA Carolinas Healthcare System

Charlotte, North Carolina, United States

Alliance Urology Specialists, PA

Greensboro, North Carolina, United States

Outcomes

Primary Outcomes

Percentage of Participants with Post-Procedure Urinary Retention requiring Catheterization

Time frame: 12 Weeks

Length of Time of Clean Intermittent Catheterization (CIC) Use

Time frame: 12 Weeks

Secondary Outcomes

Percentage of Participants with Urinary Tract Infection (UTI)

Time frame: 12 Weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.